PGIM超短期債券主動型ETF PULS 深 滬
等待開盤 06-04 09:30:00 美东时间
49.5698
0.000
0.00%
華盛通- 最 高49.57
- 今 開49.57
- 成交量 193.09万股
- 最 低 49.56
- 昨 收 49.57
- 總市值 1626.01万
- 52周最高 49.58
- 市盈率 靜 --
- 換手率 588.66%
- 52周最低 47.3702
- 委 比 10.61%
- 總股本 0.00亿
- 歷史最高 49.57
- 量 比 0.78
- 振 幅 0.02%
- 歷史最低 35.7918
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Pulsar Helium Acquires Strategic Surface Land At Topaz Helium Project, Minnesota
BRIEF-Pulsar Helium Acquires Strategic Surface Land At Topaz Helium Project, Minnesota May 29 (Reuters) - Pulsar Helium Inc PLSR.V : PULSAR HELIUM ACQUIRES STRATEGIC SURFACE LAND AT TOPAZ HELIUM PROJECT, MINNESOTA PULSAR HELIUM - PAYS $2.48 MILLION CASH FOR LAND AT TOPAZ PROJECT Source text: ID:nGNX
05-29 14:24
Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
Boston Scientific ($BSX) announced an update on their ongoing clinical study. B...
05-29 00:32
夜读 | 不在台上，但依然在场！巴菲特股东会发言及场外专访，关于市场赌博情绪、通胀应对、送给股东的“黄金法则”
不在台上，但依然在场！巴菲特股东会发言及场外专访，关于市场赌博情绪、通胀应对、送给股东的“黄金法则”>>
05-04 23:49
“超级央行周”来袭！通胀担忧飙升之际，一场市场风暴避无可避？
本周，全球金融市场将迎来极其罕见的“超级央行周”，G7各大央行将悉数登场！面对通胀与经济的双重夹击，各大央行将如何艰难走稳这根钢丝？
04-27 10:30
Johnson & Johnson To Showcase Latest Advances Across Its Electrophysiology Portfolio At 2026 HRS Annual Meeting, Including New Evidence In PFA, And Cardiac Mapping & Imaging
As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiologyA total of 17 abstracts will be presented, including new
04-21 19:51
Johnson & Johnson to debut CARTOSOUND SONATA at Heart Rhythm Society meeting
Johnson & Johnson to debut CARTOSOUND SONATA at Heart Rhythm Society meeting Johnson & Johnson will showcase electrophysiology products at Heart Rhythm Society (HRS) Annual Meeting on April 24, 2026. Event will include launch of CARTOSOUND SONATA Module for AI-assisted intracardiac echocardiography
04-21 19:45
J&J first-quarter profit beats on cancer drug Darzalex demand; raises 2026 outlook
J&J first-quarter profit beats on cancer drug Darzalex demand; raises 2026 outlook Overview U.S. healthcare conglomerate's Q1 revenue rose 9.9%, beating analyst expectations Adjusted EPS for Q1 beat analyst expectations Company raised full-year 2026 sales and adjusted EPS guidance Johnson & Johnson
04-14 18:30
